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Maternal deaths in South Africa (SA) continue to rise, despite 
the target of the fifth Millennium Development Goal (MDG) 
of a 75% reduction in maternal mortality by 2015. This target 
cannot be addressed without an appreciation of the effect of HIV 
and tuberculosis (TB) on maternal mortality in the country: the 
antenatal HIV sero-prevalence stands at 29.4%,1 and HIV is the 
most common contributory condition to maternal mortality.2 A 
number of studies have confirmed the contribution of HIV in 
maternal mortality and morbidity.3-5 
The prevalence of TB in HIV-infected pregnant women in 
SA is similar to that of the general population: approximately 
795/100 000.6 In 2009, the prevalence of active TB in HIV-
infected women attending antenatal care in Soweto, Gauteng 
Province, was found to be 688/100 000; higher than the 
prevalence in HIV-uninfected women (201/100 000).7 These 
findings were comparable with data from Durban, KwaZulu-
Natal, where prevalence rates of active TB between 1996 and 
1998 were 774/100 000 HIV-infected pregnant women; 10 
times higher than the prevalence for HIV-uninfected pregnant 
women.8
It is well established that TB and HIV are closely linked. An 
estimated 70% of adults presenting with new cases of TB in SA 
are co-infected with HIV, with TB being the most common 
cause of morbidity and mortality in HIV-infected individuals.9 
TB is a leading cause of maternal mortality and morbidity, 
causing 15% of all maternal mortality in high HIV prevalence 
settings, and 15 - 34% of indirect obstetric maternal mortality.10 
In SA between 2008 and 2010, TB accounted for 27% of 
deaths in women who died of AIDS-related complications 
during pregnancy, childbirth or the puerperium.2 The findings 
of a study in Durban revealed a 3-fold higher maternal 
mortality ratio (MMR) among HIV-infected women with TB 
(12 170/100 000 live births) compared with TB-infected HIV-
uninfected women (3 850/100 000 live births) in the absence of 
antiretroviral therapy (ART).11 Of the women diagnosed with 
TB, 79% were co-infected with HIV.11 Similarly high MMRs in 
TB/HIV-co-infected women have been observed in a number 
of studies in sub-Saharan Africa.4,12-14
The challenge of TB 
diagnosis in HIV-infected 
pregnant women
Although diagnostic approaches to TB are similar for HIV-
infected pregnant women as they are for HIV-uninfected 
and non-pregnant women, there are major challenges to the 
diagnosis of TB in the former. The symptoms of TB may be non-
specific in pregnancy, or even absent, mimicking physiological 
changes. Weight loss associated with TB disease may be 
masked by normal weight gain in pregnancy.15 The disease 
may only present post delivery in either the mother or infant.16 
Furthermore, clinical signs of HIV may overlap with those 
of TB and there may be a wide differential diagnosis.16 HIV-
infected adults may also have a high prevalence of subclinical 
TB disease,17 with HIV-infected pregnant women also less 
likely to be sputum acid-fast bacilli smear-positive than HIV-
uninfected pregnant women with TB disease.7,18 Barriers to 
accessing care may contribute further to the under-diagnosis 
of TB in these women.7
TB prevention strategies in 
the context of HIV
TB prevention, diagnosis and treatment in HIV-infected 
pregnant women should be integrated into routine maternal 
healthcare services. Key strategies adopted by the World Health 
Organization (WHO) to decrease the effect of TB on people 
living with HIV include the 3 I’s: intensified TB case finding, 
The high burden of HIV and tuberculosis (TB) among pregnant women in South Africa contributes to a high maternal mortality 
rate. Isoniazid preventive therapy (IPT) is recommended for the prevention of active TB in HIV-infected individuals, including 
pregnant women. However, there are few data regarding IPT use in the latter, with concern regarding the concurrent use of 
IPT with nevirapine in pregnancy, as both treatments are hepatotoxic. The benefit and safety of IPT in HIV-infected pregnant 
women has not been established. We recommend a simplification of HIV and TB interventions by providing triple antiretroviral 
therapy to all HIV-infected pregnant women.
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isoniazid preventative therapy (IPT); and 
infection control for TB.19  
It has been established that the use of IPT 
reduces the risk of active TB in HIV-infected 
individuals. However, this is more pronounced 
in those with a positive tuberculin skin test 
(TST).20,21 The most recent meta-analysis of 
the treatment of latent TB infection (LTBI) 
in HIV-infected individuals encompassed 12 
trials and 8 578 HIV-infected participants.20 
Overall, the treatment of LTBI reduced the 
risk of active TB by 32% (risk ratio (RR) 0.68; 
95% confidence interval (CI) 0.54 - 0.85). 
This benefit was stronger in TST-positive 
individuals (RR 0.38; 95% CI 0.25 - 0.57) than 
in TST-negative individuals (RR 0.89; 95% CI 
0.64 - 1.24). Isoniazid (INH) monotherapy 
was found to reduce mortality only in those 
who were TST-positive. However, overall, 
there was no evidence that preventive therapy 
reduced all-cause mortality.20 A randomised 
controlled trial (RCT) of 6- v. 36-month IPT 
for TB in HIV-infected adults in Botswana 
also found a benefit of IPT in TST-positive 
individuals, but no benefit for those who 
were TST-negative.21
The use of ART in HIV-infected adults 
also reduces the incidence of TB. In a meta-
analysis of 9 observational cohort studies, 
a 67% reduction in TB incidence across a 
range of CD4 cell counts and WHO disease 
stages was reported.22 TB risk reductions with 
ART occur irrespective of TST reactions.22,23 
Although the greatest absolute risk reduction 
of TB is observed in individuals with the most 
advanced immunodeficiency at baseline,22 
patients starting ART earlier, at higher CD4 
cell counts, have a 2-fold lower risk of TB 
compared with those initiating ART at lower 
CD4 cell counts.23,24 HIV-infected individuals 
starting ART with low CD4 cell counts 
remain at high risk of TB until CD4 cell count 
recovery has occurred.23
Studies have suggested that there may be 
additional benefit to concurrent IPT and 
ART.21,25,26 In a recent RCT in Khayelitsha, a 
37% reduction in the risk of TB was evident in 
individuals receiving IPT and ART compared 
with patients receiving ART only (RR 0.63; 
95% CI 0.41 - 0.94). However, the risk of 
stopping INH or placebo due to grade 3 or 4 
elevation of alanine transaminase (ALT) was 
twice as high in the patients receiving IPT 
compared with those receiving placebo and, 
overall, there was no evidence of mortality 
benefit.27 The effect of timing of IPT v. ART 
initiation has not been determined. Experts 
recommend not initiating IPT at the same 
time as ART, but rather delaying initiation 
until stabilisation on ART, at approximately 
3 months.22,28 
The safety of IPT in 
pregnant women
Current national and international guidelines 
recommend the use of IPT for 6 months for 
all HIV-infected adults asymptomatic for 
TB, including pregnant women.9,29 WHO 
advises that, although not a requirement for 
IPT initiation in HIV-infected individuals, 
TSTs may identify those who would benefit 
most from IPT. The American Thoracic 
Society (ATS) recommends a TST for the 
diagnosis of LTBI in pregnant women with 
a specific risk factor for LTBI or who are 
at risk for progression to TB disease. This 
includes women who are HIV-infected 
or who have a recent TB case contact. 
Although ATS acknowledge that treatment 
for LTBI in pregnancy is controversial, they 
do recommend such treatment for cases of 
recent TB or HIV infection where there is 
an increased risk of haematogenous spread 
of organisms to the placenta, as well as in 
situations with a high risk of progression of 
LTBI to disease.30 Guidelines do indicate that 
IPT can be administered during pregnancy, 
but it is unclear when and if IPT should be 
given if the pregnant woman is receiving ART.
There is little evidence available on IPT 
use in HIV-uninfected pregnant women in 
general. Furthermore, to our knowledge, there 
is no evidence available of the effectiveness 
of IPT in reducing TB risk in HIV-infected 
pregnant women.
In a study which modelled the cost-
effectiveness and outcomes of different 
treatment strategies for LTBI in pregnancy, 
antepartum IPT was anticipated to result in the 
fewest cases of TB and be more cost-effective 
than no treatment or delaying treatment until 
postpartum.31 Ante- and postpartum IPT was 
predicted to be less costly and result in a 
higher life expectancy than no treatment, 
despite a higher mortality rate due to hepatitis 
in the antepartum group.31 However, HIV 
infection and the use of ART were not taken 
into account.
INH is not teratogenic, even if given 
during the first trimester,32 but it has 
a number of known adverse effects which 
include neurological toxicity, skin rash and 
hepatotoxicity. Reported rates of INH-
associated clinical and biochemical hepatitis 
range from 0% to 5%.28 In a systematic review 
of the risk of age-related hepatotoxicity in LTBI 
treatment, a median hepatotoxicity rate of 1.8% 
was reported. Studies with close monitoring 
of hepatotoxicity reported lower rates of 
hepatotoxicity than those without monitoring. 
In studies with available information, there was 
only one reported case of hospitalisation and 
no reported cases of mortality.33 A comparison 
of treatment with rifampicin for 4 months v. 
INH for 9 months found rates of hepatotoxicity 
of 1.4 - 5.2% in the latter.34
Although it is not conclusive whether 
the side-effects of INH are worsened by 
pregnancy, 2 studies have suggested that 
pregnant or postpartum women may be at 
higher risk of hepatotoxicity.30 Pyridoxine 
supplementation is recommended in HIV-
infected and pregnant individuals taking INH 
to prevent neurological toxicity.30
The rate of INH-associated hepatitis in 
HIV-infected individuals appears to be 
similar to that of the general population.35 
In a Brazilian study of HIV-infected patients 
receiving IPT (with or without ART), 1.2% 
of participants had adverse reactions leading 
to discontinuation of IPT.36 In a study of 
1 762 HIV-infected individuals receiving IPT 
in Botswana, 1.1% developed hepatitis, and 
one death was reported.28 In Khayelitsha, a 
hepatitis risk of 2.9% was reported in patients 
receiving IPT and ART.27 
Some antiretroviral drugs are known to be 
associated with significant adverse effects, 
including hepatotoxicity. A 4.4% prevalence 
of grade 3 - 4 hepatotoxicity and 7% 
prevalence of grade 1 - 2 hepatotoxicity have 
been associated with nevirapine (NVP) use 
in HIV-infected pregnant women. The rate 
of NVP side-effects is higher in women with 
CD4 counts >250 cells/mm3.37 NVP is part 
of the first-line regimens used to treat HIV-
infected pregnant women with CD4 counts 
≤350 cells/ mm3 or WHO clinical stage 3 or 4 
conditions in SA. 
Increased rates of INH-associated hepatitis 
have been reported in patients receiving NVP-
containing ART regimens compared with 
those receiving efavirenz (EFV)-containing 
regimens. In a previous study, the use of 
ART by 480 patients was not associated with 
INH-hepatitis, although those receiving NVP 
had a higher rate of hepatitis (2%) than those 
receiving EFV (0.9%). Interestingly, a CD4 
cell count <200 cells/mm3 was associated with 
INH hepatitis (RR 2.80; 95% CI 1.13 - 6.84).28
Conclusion
There is a high burden of HIV and TB among 
pregnant women in SA, contributing to a high 





MMR. Despite ART availability in the country, 
the recent maternal mortality survey showed 
that the majority of women who died from 
HIV did not access ART. If we are to progress 
towards the MDG targets, interventions need 
to be safe, easy to implement and simplified 
to maximise early nurse initiation of ART. 
IPT initiation after ART in pregnancy adds 
additional steps to antenatal care, which is 
currently under-resourced. This may further 
burden the programme and compromise other 
areas of care, for a benefit apparently limited to 
TST-positive individuals and that, to date, has 
no evidence of efficacy in pregnancy.  
Screening all pregnant women for TB 
and HIV is imperative. Those with TB 
disease should be treated accordingly, with 
contact tracing and screening of household 
contacts. Although not currently stipulated 
in guidelines, all HIV-infected pregnant 
women should be considered for initiation 
onto combination ART. With this approach, 
IPT initiation may be better deferred until the 
postpartum period. Triple ART for all HIV-
infected pregnant women will reduce mother-
to-child HIV transmission, adverse pregnancy 
outcomes, maternal mortality, horizontal 
transmission to uninfected partners and, 
specifically, the incidence of TB disease.
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